# We have a drug shortage problem—here’s how we can solve it | Caroline Schober | TEDxMedUniGraz

Source: https://www.youtube.com/watch?v=5UgQV9d5lCk
Recap page: https://rapidrecap.app/video/5UgQV9d5lCk
Generated: 2026-01-12T07:32:39.108+00:00

---
## Quick Overview

The speaker, Caroline Schober, asserts that Europe faces a critical drug shortage problem because regulatory frameworks prioritize price and supply chain resilience over ensuring patient access to essential medicines, proposing that the EU must foster a true single market where local production and innovative frameworks balance safety and cost to prevent future shortages.

**Key Points:**
- Europe currently faces a critical shortage of essential medicines, where 70% of active pharmaceutical ingredients (APIs) for these drugs come from China and India (01:54, 02:05).
- The cost of making a batch of essential medicine, like penicillin or insulin, in Europe is 20% to 50% higher than manufacturing elsewhere, leading to strategic stock-piling and eventual shortages (02:38, 03:17).
- The current regulatory environment, designed to boost local production and balance safety, inadvertently creates a nightmare scenario where costs and regulatory burden outweigh resilience (05:12, 05:54).
- Pharmaceutical companies are incentivized to buy the cheapest generics abroad and sell European-made drugs at the highest price, often resulting in billions of euros worth of waste from expired stock (05:53, 06:00).
- Austria hosts Europe's only fully integrated penicillin production plant, which is now threatened by these skewed priorities (03:08, 03:14).
- Schober argues that the EU needs a true single market that values resilience and innovation alongside price, otherwise, the system favors short-term cost savings over long-term health security (05:58, 08:01).
- The speaker concludes by stating that securing the supply chain and prioritizing medicine safety must be a regulatory requirement, not just an option (10:23, 11:32).

![Screenshot at 00:16: Speaker Caroline Schober, dressed in a white suit, walks onto the stage at the TEDxMedUniGraz event, ready to present her argument on the drug shortage crisis.](https://ss.rapidrecap.app/screens/5UgQV9d5lCk/00-00-16.jpg)

**Context:** Caroline Schober delivers a TEDx talk at TEDxMedUniGraz addressing the structural fragility of Europe's pharmaceutical supply chain, specifically focusing on the shortage of essential, life-saving medicines like antibiotics and insulin. She highlights the economic disincentives that favor cheap, distant sourcing over local, resilient manufacturing, arguing that the current regulatory focus on cost is creating a crisis where patients suffer due to lack of supply.

## Detailed Analysis

Caroline Schober opens by painting a picture of a world where treatable cancer or a simple scratch on the knee could lead to death because essential medicines are unavailable, noting that in Austria, one of the most developed countries, essential medicines like antibiotics and insulin are often unavailable or accessible only through complicated routes. She points out that 70% of the active pharmaceutical ingredients (APIs) for these essential medicines come from just two countries: China and India. This dependence creates systemic vulnerability. She contrasts the high cost of manufacturing in Europe (20% to 50% more expensive) with the low cost of buying generics abroad, which leads pharmaceutical companies to stockpile locally produced drugs until they expire, wasting billions of euros. The core problem, Schober argues, is that regulatory frameworks, like the EU's Medicinal Products Act, are designed to boost local production and balance safety, but they fail to prioritize resilience and fail to account for the social cost of shortages. She cites that for every euro spent on medicine safety, the cost of shortages—including canceled surgeries and failed treatments—is far greater. Schober proposes a shift in focus: regulations must mandate that European production, which adheres to high safety and environmental standards, be prioritized and supported financially, perhaps by valuing resilience and local supply chains equally with price considerations. The solution, she suggests, lies in creating a true single market where European manufacturers can operate under fair conditions, ensuring that life-saving medicines are available locally and consistently, rather than relying on fragile global logistics.

### The Scale of the Problem

- Simple scratch knee could kill your child
- 70% of active pharmaceutical ingredients for essential medicines come from China and India
- 100% of penicillin production in Europe is currently at risk.

### Economic Disincentives

- European manufacturing costs 20-50% more than production elsewhere
- Companies maximize profit by buying cheap generics abroad and selling European stock until it expires, wasting billions of euros worth of product.

### Regulatory Failures

- The EU's regulatory framework prioritizes price and resilience, but the reality is that the system is set up to favor short-term cost savings (e.g., 1.6 trillion euros spent annually on healthcare in the EU) over long-term supply security.

### The Proposed Solution

- Governments and the EMA must collaborate to create frameworks that value resilience and innovation alongside price
- This involves supporting local, continuous manufacturing and avoiding batch production cycles that favor scarcity.

### The Cost of Inaction

- Current policies lead to shortages of cancer drugs and antibiotics, and the social cost of these shortages (canceled surgeries, suffering) outweighs the cost of investing in robust, local supply chains.

![Screenshot at 00:04: The opening slide displays the event branding 'TEDx MedUniGraz' alongside logos of various sponsors and partners.](https://ss.rapidrecap.app/screens/5UgQV9d5lCk/00-00-04.jpg)
![Screenshot at 00:16: Speaker Caroline Schober, introduced by name overlay, walks onto the stage wearing an all-white pantsuit.](https://ss.rapidrecap.app/screens/5UgQV9d5lCk/00-00-16.jpg)
![Screenshot at 00:50: The large screen behind the speaker displays the TEDx logo with a red, shadowy graphic silhouette, emphasizing the gravity of the topic.](https://ss.rapidrecap.app/screens/5UgQV9d5lCk/00-00-50.jpg)
![Screenshot at 01:07: The speaker gestures broadly to the audience while discussing the global nature of medicine shortages across Europe.](https://ss.rapidrecap.app/screens/5UgQV9d5lCk/00-01-07.jpg)
![Screenshot at 03:03: The speaker uses hand gestures to emphasize a key statistic: Austria hosts Europe's only fully integrated penicillin production plant.](https://ss.rapidrecap.app/screens/5UgQV9d5lCk/00-03-03.jpg)